⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JNJ News
Johnson & Johnson
Medical Devices Market Size Worth USD 1,209.42 Bn by 2035 Fueled by Advances in Diagnostic Technologies
globenewswire.com
GEHC
MDT
ABT
JNJ
Poxel publie ses résultats financiers pour le premier semestre 2025
businesswire.com
MRK
JNJ
Poxel Publishes Its Financial Results for the First Half of 2025
businesswire.com
JNJ
Global Medical Device Contract Manufacturing Market is Predicted to Cross the USD 190 Billion Mark by 2032, Owing to the Rising Demand for Advanced Healthcare Solutions | DelveInsight
globenewswire.com
TMO
PFE
AMGN
BMY
MRK
DHR
ABBV
GOOG
MSFT
JNJ
MDT
BSX
SYK
EW
ISRG
EMR
BIOX
EXAS
QRVO
TER
ADI
TXN
ON
INTC
NVDA
AMD
HPQ
DELL
IBM
GE
FISV
ADP
PAYX
NOW
CRM
ORCL
SAP
ADSK
CDNS
SNPS
AMAT
INFY
HPE
LOGI
ATHM
BIIB
GILD
REGN
VRTX
AMRN
AZN
LLY
NVS
CRSP
EDIT
NTLA
ALNY
INCY
XRAY
COO
MASI
IRTC
MRNA
EMB
ADMA
ICUI
HOLX
LH
DGX
RDNT
EVTC
AFYA
CHKP
DDOG
SMCI
ALGN
THRY
PTC
MCHP
NXPI
QCOM
SWKS
MU
WDC
STX
Cocaine Use Disorder Market Intelligence Report 2025-2032: Rapid Growth of Telepsychiatry Platforms Delivering Remote Treatment
globenewswire.com
ALKS
PFE
JNJ
Global Diabetic Eye Disease Devices Market Forecast (2025-2032) Featuring Strategic Analysis of Carl Zeiss, Topcon, Heidelberg Engineering, NIDEK, Canon Medical Systems and More - ResearchAndMarkets.com
businesswire.com
TOPC
NC
ALC
BLCO
JNJ
Surgical Robots Market worth $27.14 billion by 2030 | MarketsandMarkets™
prnewswire.com
ISRG
STX
MD
SN
ZBH
JNJ
Medical Devices Market Worth USD 955 Billion by 2030 as Conventional Devices Lead and AR/VR Platforms Grow at 7.78% CAGR, Says Mordor Intelligence
globenewswire.com
MDT
GEHC
PHG
ABT
HON
ZBH
SYK
JNJ
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI®▼ (teclistamab) plus DARZALEX® (daratumumab) subcutaneous formulation as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
globenewswire.com
JNJ
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
prnewswire.com
JNJ